• 1
    NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
  • 2
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
  • 3
    Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009; 27: 5124-5130.
  • 4
    Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006; 24: 4620-4625.
  • 5
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-1123.
  • 6
    O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331: 502-507.
  • 7
    Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34: 1274-1281.
  • 8
    Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000; 45: 291-297.
  • 9
    Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg Med Chem. 2000; 8: 1697-1706.
  • 10
    Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15: 110-115.
  • 11
    Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 346-353.
  • 12
    Yu CS, Kim TW, Kim JH, et al. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1020-1026.
  • 13
    Greene F, Page D, Fleming I, Abt M. American Joint Committee on Cancer staging manual. 6th ed. New York: Springer, Inc., 2002.
  • 14
    Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 13-47.
  • 15
    Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006; 24: 3542-3547.
  • 16
    Kim DY, Jung KH, Kim TH, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 378-384.
  • 17
    Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006; 66: 1378-1383.
  • 18
    Yerushalmi R, Idelevich E, Dror Y, et al. Preoperative chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. J Surg Oncol. 2006; 93: 529-533.
  • 19
    Chan AK, Wong AO, Jenken DA. Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer—is it equivalent to 5-FU infusion plus leucovorin and radiotherapy? Int J Radiat Oncol Biol Phys. 2010; 76: 1413-1419.
  • 20
    O'Connell MJ, Wolmark N, Beart R, Petrelli N. Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2005; 23: 933-934.
  • 21
    Kim CW, Kim JH, Yu CS, et al. Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery. Int J Radiat Oncol Biol Phys. 2010; 78: 156-163.
  • 22
    Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer. 2007; 97: 1333-1337.
  • 23
    De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol. 2006; 17: 246-251.
  • 24
    Dupuis O, Vie B, Lledo G, et al. Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study. Oncology. 2007; 73: 169-176.
  • 25
    Ngan SY, Michael M, Mackay J, et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer. 2004; 91: 1019-1024.
  • 26
    Slampa P, Kocakova I, Sefr R, et al. Neoadjuvant treatment for locally advanced rectal adenocarcinoma with concomitant radiotherapy and oral capecitabine. J BUON. 2004; 9: 33-40.
  • 27
    Crane CH, Sargent DJ. Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? J Clin Oncol. 2004; 22: 2978-2981.
  • 28
    Holm T, Johansson H, Cedermark B, Ekelund G, Rutqvist LE. Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Br J Surg. 1997; 84: 657-663.
  • 29
    Kouloulias VE, Bosset JF, van Tienhoven G, Davis BJ, Pierart M, Poortmans P. Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer: evaluation of the individual case review procedure. Eur J Cancer. 2002; 38: 1849-1856.